Aldeyra Therapeutics, INC. 8-K Filing
Ticker: ALDX · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1341235
Sentiment: neutral
Filing Stats: 1,396 words · 6 min read · ~5 pages · Grade level 15.7 · Accepted 2025-12-15 19:49:49
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- aldx-20251215.htm (8-K) — 67KB
- aldx-ex99_1.htm (EX-99.1) — 21KB
- 0001193125-25-319638.txt ( ) — 208KB
- aldx-20251215.xsd (EX-101.SCH) — 30KB
- aldx-20251215_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. As reported in Item 7.01 of this Current Report on Form 8-K, on December 15, 2025, the Company issued the Press Release to announce the PDUFA extension for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Aldeyra Therapeutics, Inc. dated December 15, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated: December 16, 2025 3